Media Contacts
photo:Caitlin Pearson
Caitlin Pearson
Corporate Communications
Share this release
Share on: Twitter
Share on: Facebook
Share on: LinkedIn
Latest news
03
August
2016

Hardman Research: Major progress in orthopaedics

Major progress towards orthopaedics approvals: Tissue Regenix is now in the commercialisation phase having validated its dCELL® technology to produce 'like-for-like' tissue specific, structure-preserving scaffolds for use in multiple clinical settings. DermaPure has started well in the US for treating chronic wounds and traction will increase now that it is widely reimbursed by Medicare providers. But newsflow in the next 12 months is likely to be dominated by the approval and launch of the orthopaedics products for meniscal and tendon repairs. Despite short term monthly cashburn of c., TRX is building long term value, evidenced by 32p NPV driven by three core product areas.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/tissue-regenix--documents/03-08-16-major-progress-towards-orthopaedics-approvals

To contact us:

Hardman & Co

11/12 Tokenhouse Yard

EC2R 7AS

Contact: Dr Martin Hallmh@hardmanandco.com 

Dr Dorothea Hill

dmh@hardmanandco.com

Dr Gregoire Pave

gp@hardmanabdco.com

Telephone: +44 20 7929 3399

Follow us on Twitter @HardmanandCo